News
AstraZeneca is backing up its big investments in antibody-drug conjugates (ADCs) with the construction of a $1.5bn new facility in Singapore.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback